What is the prediction for CRISPR Therapeutics stock in 2026?
Wall Street equity research analysts tracking CRISPR Therapeutics AG (CRSP) maintain a consensus "Buy" rating, with average twelve-month price predictions hovering around $71 to $86 per share. Financial forecasters emphasize that future stock performance will depend heavily on the commercial adoption rate and market expansion of Casgevy, its landmark gene-editing therapy for sickle cell disease and beta-thalassemia. While high volatility remains characteristic of clinical-stage biotechnology equities, bullish analysts highlight its robust cash position and expanding clinical pipeline targeting oncology and autoimmune conditions as key long-term valuation drivers.
Related FAQs
Yes, CS Bank offers Zelle as a convenient and integrated digital payment service.
No, Charles River Laboratories International (CRL) does not pay a dividend to its shareholders.
While CRISPR-Cas9 remains a cornerstone gene-editing technology, next-generation genetic engineering tools such as base editing, prime editing, and epigenetic editing are advancing rapidly to complement or replace standard double-stranded DNA cutt...
CRISPR gene-editing technologies are continuously advancing at an extraordinary pace, exhibiting enhanced precision, minimized off-target effects, and expanded clinical capabilities.
Diseases that are classified as completely genetic are caused directly by mutations or alterations in a single specific gene, known as monogenic or Mendelian disorders.
Jeff Bezos has directed substantial private capital and strategic investment toward groundbreaking technological frontiers, most notably in commercial space exploration through Blue Origin, artificial intelligence advancements, and life sciences r...
Bill Gates, through the Bill & Melinda Gates Foundation, has provided substantial financial backing and research grants to major gene-editing companies working on advanced therapies.
Diseases or traits inherited exclusively through the father are linked directly to genetic material residing on the Y chromosome, since fathers pass their single Y chromosome down solely to their biological sons.
Yes, Bill Gates's clean energy investment fund, Breakthrough Energy Ventures (BEV), announced an investment in Fervo Energy in 2018. Fervo Energy is a startup focused on pioneering "Enhanced Geothermal Systems" (EGS) technology.
Evaluating the five-year stock trajectory of major gene-editing companies requires analyzing clinical trial progression, intellectual property licensing agreements, and the path toward commercial revenue generation from revolutionary CRISPR-based ...
Yes, Cathie Wood’s ARK Invest maintains a position in GitLab Inc. (GTLB) within its portfolio.
CRISPR Therapeutics AG (CRSP) is a pioneering clinical-stage biopharmaceutical company focused on developing revolutionary gene-editing therapies utilizing CRISPR/Cas9 technology to treat serious genetic diseases.
As of July 2026, while CRISPR Therapeutics holds a Buy consensus rating among market professionals, it is not universally categorized as a Strong Buy.
The Zacks forecast for CRISPR Therapeutics AG anticipates a quarterly loss of approximately $1.10 per share for the upcoming earnings report, marking a notable year-over-year improvement compared to previous historical periods.
Companies operating within the CRISPR gene-editing and biotechnology sector are frequently viewed as potential strategic acquisition targets for massive global pharmaceutical conglomerates seeking innovative genetic medicine pipelines.